ALKERMES | ALKS - Assets


ALKERMES reported $4.39B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
ALKERMES USD 4.39B 135.05M Jun/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
J&J USD 201.06B 167M Jun/2026
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 128.68B 8.18B Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Otsuka Holdings JPY 4.4T 186.7B Jun/2026
Ovoca Bio EUR 2.07M 414K Dec/2025
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026